Literature DB >> 7436533

Immune responses to liver membrane antigens in patients with cystic fibrosis and liver disease.

G Mieli-Vergani, H T Psacharopoulos, A M Nicholson, A L Eddleston, A P Mowat, R Williams.   

Abstract

Biliary obstruction by viscid mucus, although important, may not be the only factor for the development of liver disease in some patients with cystic fibrosis. In the present study the relationship between immune responses to liver antigens and the presence of liver damage was investigated using the leucocyte migration test and lymphocyte cytotoxicity to isolated rabbit hepatocytes. Inhibition of leucocyte migration by purified liver-specific lipoprotein, derived from hepatocyte plasma membrane, was found in 9 of 11 children with liver disease, but in only 5 of 14 with cystic fibrosis and no overt liver disease (P < 0.025). Lymphocyte toxicity to isolated rabbit hepatocytes was significantly increased in 10 of 13 children with liver disease, but in only 6 of 29 children without liver disease (P < 0.001). Experiments using lymphocyte subpopulations showed that the cytotoxicity was mediated by a non-T-cell population and could be blocked with liver-specific lipoprotein in 7 out of 10 cases, suggesting that the reaction in these patients was specifically directed against liver-specific lipoprotein. The study suggests that sensitisation against liver membrane antigens, whether arising primarily or secondarily in some way to other hepatic lesions, may contribute to the progression of liver damage in cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7436533      PMCID: PMC1626989          DOI: 10.1136/adc.55.9.696

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  25 in total

1.  Critique of present in vitro methods for the detection of cell-mediated immunity.

Authors:  J Brostoff
Journal:  Proc R Soc Med       Date:  1974-06

2.  Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system.

Authors:  R M Zinkernagel; P C Doherty
Journal:  Nature       Date:  1974-04-19       Impact factor: 49.962

3.  Lymphopenia and change in distribution of human B and T lymphocytes in peripheral blood induced by irradiation for mammary carcinoma.

Authors:  J Stjernswärd; M Jondal; F Vánky; H Wigzell; R Sealy
Journal:  Lancet       Date:  1972-06-24       Impact factor: 79.321

4.  Portal hypertension in cystic fibrosis.

Authors:  K R Tyson; S R Schuster; H Shwachman
Journal:  J Pediatr Surg       Date:  1968-04       Impact factor: 2.545

5.  Serum alkaline phosphatase in cystic fibrosis. Interpretation of elevated values based on electrophoretic isoenzyme analyses.

Authors:  T F Boat; C F Doershuk; R C Stern; L W Matthews
Journal:  Clin Pediatr (Phila)       Date:  1974-06       Impact factor: 1.168

6.  Evaluation of the leucocyte migration test as a measure of delayed hypersensitivty in man. Suppression of migration inhibition by puromycin.

Authors:  C G Mitchell; M G Smith; P L Golding; A L Eddleston; R Williams
Journal:  Clin Exp Immunol       Date:  1972-08       Impact factor: 4.330

7.  Liver scanning and liver function in cystic fibrosis.

Authors:  J Feigelson; Y Pecau; R Perez
Journal:  Acta Paediatr Scand       Date:  1972-05

8.  Isolation of leucocytes from human blood. A two-phase system for removal of red cells with methylcellulose as erythrocyte-aggregating agent.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

9.  An in vitro assay for cellular hypersensitivity in man.

Authors:  R E Rocklin; O L Meyers; J R David
Journal:  J Immunol       Date:  1970-01       Impact factor: 5.422

10.  A report on sixty-five patients over 17 years of age.

Authors:  H Shwachman; L L Kulczycki; K T Khaw
Journal:  Pediatrics       Date:  1965-11       Impact factor: 7.124

View more
  4 in total

1.  Prevalence of liver disease in cystic fibrosis.

Authors:  R Scott-Jupp; M Lama; M S Tanner
Journal:  Arch Dis Child       Date:  1991-06       Impact factor: 3.791

Review 2.  Current clinical management of hepatic problems in cystic fibrosis.

Authors:  M S Tanner
Journal:  J R Soc Med       Date:  1986       Impact factor: 5.344

Review 3.  The gallbladder and biliary tract in cystic fibrosis.

Authors:  Michael P Curry; John E Hegarty
Journal:  Curr Gastroenterol Rep       Date:  2005-05

4.  Liver cirrhosis in cystic fibrosis--therapeutic implications and long term follow up.

Authors:  J Feigelson; C Anagnostopoulos; M Poquet; Y Pecau; A Munck; J Navarro
Journal:  Arch Dis Child       Date:  1993-05       Impact factor: 3.791

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.